Bacterial Vaginosis Drug Market Scope And Analysis

Report Code : TIPRE00018820
Category : Life Sciences

Status : Published
No. of Pages : 184

Buy Now

Bacterial Vaginosis Drug Market Trends and Scope by 2031

Buy Now

Bacterial Vaginosis Drug Market Report Scope

Report Attribute	Details
Market size in 2024	US$ 2.15 Billion
Market Size by 2031	US$ 3.82 Billion
Global CAGR (2024 - 2031)	8.3%
Historical Data	2021-2023
Forecast period	2024-2031
Segments Covered	By Type Prescription Drugs Over-the-counter Drugs By Route Of Administration Oral Vaginal Topical By Dosage Form Pills Creams Gel Solution or Washes By Distribution Channel Hospital Pharmacies Online Pharmacies Retail Pharmacies
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Bayer AG Pfizer Inc Sanofi SA Starpharma Holdings Limited Viatris Inc Glenmark Pharmaceuticals Ltd Lupin Ltd Sun Pharmaceutical Industries Ltd Organon Co Duchesnay Inc Canada

Bacterial Vaginosis Drug Market News and Recent Developments

The bacterial vaginosis drug market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments witnessed in the bacterial vaginosis drug market are listed below:

VivaGel BV salesStarpharma inks partnership to distribute VivaGel BV product in MENA region and distribution agreement – MENA region. (Source: Starpharma Holdings Limited, Press Release, January 2024)
Organon’s XACIATO (clindamycin phosphate) Vaginal Gel 2% was made available nationwide to treat bv in females aged 12 and older. (Source: Lupin, Press Release, January 2024)
Glenmark Pharmaceuticals received ANDA approval for Metronidazole Vaginal Gel, 0.75%. (Source: Glenmark Pharmaceuticals Inc., Press Release, January 2022)
Lupin announced sNDA approval by the FDA for SOLOSEC (secnidazole) to extend its use in adolescents for the treatment of both bacterial vaginosis and trichomoniasis in females. (Source: Lupin, Press Release, February 2022)

Bacterial Vaginosis Drug Market Report Coverage and Deliverables

The "Bacterial Vaginosis Drug Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

Bacterial vaginosis drug market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Bacterial vaginosis drug market trends, as well as market dynamics such as drivers, restraints, and key opportunities
Detailed PEST and SWOT analysis
Bacterial vaginosis drug market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the bacterial vaginosis drug market
Detailed company profiles